Forbion Ventures raises €2bn across multiple funds, its largest ever

Team S · 2024-10-16T09:57:53.000Z

Forbion, a leading European life sciences venture capital firm, has announced the successful closing of its largest fundraising effort to date, amassing an impressive €2 billion across multiple funds. This significant capital raise will enable Forbion to invest in approximately 30 biotechnology companies, fueling innovation and growth in the life sciences sector. - Record-breaking fundraise : Forbion secures €2 billion, marking its largest funding round ever - Multiple funds : The capital is spread across various funds, including Growth Opportunities Fund II and Venture Fund VI - Investment strategy : Focus on late-stage companies and early-stage biotechs in Europe and North America - Target companies : Approximately 30 biotech firms to benefit from the raised capital Fund Breakdown **Growth Opportunities Fund II** - Raised: €600 million - Focus: Late-stage private companies and small public companies in Europe and North America **Venture Fund VI** - Raised: €470 million - Focus: Early-stage biotechs in Europe and North America This substantial funding injection is expected to have a significant impact on the biotech industry, particularly in Europe and North America. It will provide crucial support for companies developing innovative treatments and technologies, potentially accelerating the development of new therapies and medical breakthroughs. Forbion's successful fundraising effort underscores the continued investor interest in the life sciences sector and bodes well for the future of biotech innovation.

Member Login Get Access

Back to feed

Forbion Ventures raises €2bn across multiple funds, its largest ever | Newnex